View all CPC CME

Share a PER® activity with your colleagues or friends. Connect with the PER® social network.



Accreditation/ Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669 for 1.5 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AbbVie, AstraZeneca, BeyondSpring Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Celgene Corporation, Genentech, Ignyta, Lilly, Merck Sharp & Dohme Corp, Novartis Pharmaceuticals Corporation, and Takeda Oncology.

For further information concerning Lilly grant funding visit www.lillygrantoffice.com.


Community Practice Connections™: 18th Annual International Lung Cancer Congress®

Release Date: October 31, 2017
Expiration Date: October 31, 2018
Media: Internet - based

 

Activity Overview

Community Practice Connections™: 18th Annual International Lung Cancer Congress® consists of a series of interactive clinical vignettes, short video interviews of leading experts in lung cancer, and short summaries of clinical data related to these issues. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting.

CME/CE Activity Table of Contents

  • Module 1: A Patient With Unresctable, Stage III NSCLC
  • Module 2: A Patient With Advanced Lung Adenocarcinoma
  • Module 3: A Patient With Advanced, Squamous NSCLC
  • Module 4: A Patient With ALK-rearranged NSCLC
  • Module 5: A Patient With EGFR Mutation-Positive NSCLC

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a cme/ce certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a cme/ce certificate upon completion of these steps.

Target Audience

This educational activity is directed toward oncologists, nurse practitioners (NPs), nurses, and physician assistants (PAs) involved in the treatment and management of patients with lung cancers. Pharmacists, researchers, fellows, and other healthcare professionals interested in the treatment of lung cancers may also participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Delineate testing strategies for the diagnosis and identification of biomarkers which can be used to facilitate clinical decision making in multiple lines of lung cancer care
  • Explain evolving treatment strategies for early-stage and locally advanced lung cancer
  • Determine optimized sequencing strategies for the management of advanced lung cancer based on clinical data sets, performance status, and tumor characteristics
  • Assess current data sets and ongoing clinical trials evaluating single agent and combination immunotherapeutic approaches
  • Place recent clinical trial results on chemotherapeutic, targeted, and immunotherapeutic strategies in the context of current treatment standards and evolving paradigms in the management of lung cancer
  • Explain the current status of cooperative group trials and methods to facilitate participation in clinical trials that are assessing emerging strategies to treat lung cancer

Faculty, Staff, and Planners' Disclosures

Faculty

David R. Gandara, MD
Professor of Medicine
Division of Hematology/Oncology
Director, Thoracic Oncology Program
Senior Advisor to the Director
UC Davis Comprehensive Cancer Center
Sacramento, CA

Disclosure: Grant Research Support: AstraZeneca/Medi, Bristol-Myers Squib, Clovis, Genentech, Johnson & Johnson, Lilly, Merck, Novartis; Consultant: Ariad, AstraZeneca, Boehringer-Ingelheim, Celgene, Clovis, Genentech, Guardant Health, Lilly, Merck, Mirati, Novartis, Pfizer

Sarah B. Goldberg, MD, MPH
Assistant Professor of Internal Medicine
Medical Oncology
Yale Cancer Center
New Haven, CT
 

Disclosure: Grant Research Support: AstraZeneca; Other: Advisory Board for AstraZeneca

Roy S. Herbst, MD, PhD
Ensign Professor of Medicine (Medical Oncology)
Professor of Pharmacology
Chief of Medical Oncology
Associate Director for Translational Research
Yale Cancer Center
Yale School of Medicine
New Haven, CT

Disclosure: Grant Research Support: Genentech, Merck; Consultant: AstraZeneca, Eli Lilly, Genentech/Roche, Merck, Pfizer

Christine M. Lovly, MD, PhD
Assistant Professor of Medicine, Division of Hematology-Oncology
Assistant Professor of Cancer Biology
Vanderbilt University School of Medicine
Vanderbilt Ingram Cancer Center
Nashville, TN

Disclosure: Consultant: Novartis, Pfizer, Ariad, Genoptix, AstraZeneca, Takeda

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

CME/CE Provider Contact Information

Physicians’ Education Resource®, LLC
2 Clarke Drive
Suite 110
Cranbury, NJ 08512
info@gotoper.com

Hardware And Software Requirements 

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)

  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Minimum System Requirements (Mac OS)

  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise




Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
2627282930
Filter By